Spruce Biosciences to Participate in March Investor Conferences

Rhea-AI Summary

Spruce Biosciences (NASDAQ: SPRB), a late-stage biopharmaceutical company, announced its participation in two virtual investor conferences in March 2022. The Cowen 42nd Annual Health Care Conference will occur from March 7-9, featuring a company presentation on March 9 at 11:10 a.m. ET. The Oppenheimer 32nd Annual Healthcare Conference will take place from March 15-17, with a fireside chat on March 16 at 8:00 a.m. ET. Webcasts of these events will be accessible on the company's investor relations website.

SAN FRANCISCO--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place virtually in March.

• Cowen 42^nd Annual Health Care Conference
  Date: March 7-9, 2022
  Format: Company presentation (March 9 at 11:10 a.m. ET) and 1x1 meetings

• Oppenheimer 32^nd Annual Healthcare Conference
  Date: March 15-17, 2022
  Format: Fireside chat (March 16 at 8:00 a.m. ET) and 1x1 meetings

Interested parties can access the webcast for each conference presentation from the Events section of the company’s investor relations website at https://investors.sprucebiosciences.com. A replay of the webcasts will be available after the conclusion of the live presentations for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220301005046/en/

Media Contact

Will Zasadny

Canale Communications

(619) 961-8848

will.zasadny@canalecomm.com

media@sprucebiosciences.com

Investors

Xuan Yang

Solebury Trout

(415) 971-9412

xyang@soleburytrout.com

investors@sprucebiosciences.com

Source: Spruce Biosciences, Inc.

FAQ

When is Spruce Biosciences participating in the Cowen conference?

Spruce Biosciences will participate in the Cowen 42nd Annual Health Care Conference from March 7-9, 2022, with a presentation scheduled for March 9 at 11:10 a.m. ET.

What is the date for Spruce Biosciences' Oppenheimer conference participation?

Spruce Biosciences will take part in the Oppenheimer 32nd Annual Healthcare Conference from March 15-17, 2022, with a fireside chat on March 16 at 8:00 a.m. ET.

How can I access the webcasts for the Spruce Biosciences conferences?

The webcasts for the Spruce Biosciences conferences can be accessed on the company’s investor relations website.

What is the main focus of Spruce Biosciences?

Spruce Biosciences focuses on developing novel therapies for rare endocrine disorders with significant unmet medical needs.

What is tildacerfont's significance for Spruce Biosciences?

Tildacerfont is Spruce Biosciences' primary product candidate, aimed at treating classic congenital adrenal hyperplasia and a form of polycystic ovary syndrome.